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Malignant gliomas are aggressive cancers, 
characterized by innate resistance to ther-
apies and short patient survival.1 However, 
the prognosis of these tumors is chang-
ing, with the advent of molecular-targeted 
therapies aimed at the oncogenic signaling 
associated with tumor specific prolifera-
tion, invasion and angiogenesis pathways.
There is renewed hope that the unprece-
dented amount of basic science knowledge 
acquired in recent years will translate into
improved clinical outcomes.
AP-1 (activating protein-1) is a collec-
tive term referring to dimeric transcrip-
tion factors composed of Jun, Fos or ATF 
(activating transcription factor) subunits 
that bind to a common DNA site, the 
AP-1-binding site.2 There is a high level 
of complexity in the dimer’s formation, as 
pairing can consist of both homodimers 
and heterodimers of Jun (v-Jun, c-Jun, 
JunB, JunD), Fos (v-Fos, c-Fos, FosB, Fra-
l, Fra-2) or activating transcription factor 
(ATF2, ATF3/LRF1, B-ATF) bZIP (basic 
region leucine zipper) proteins.3 In addi-
tion, the heterodimers display distinguish-
able DNA binding specificities from each 
other and from their parental homodi-
mers,3 raising the question of the different 
biological functions each and every one of 
these dimers play both in normal physiol-
ogy and in the pathophysiology of human 
diseases.4 AP-1 has been implicated in a 
large variety of biological processes includ-
ing cell differentiation, proliferation,5 
apoptosis6 and oncogenic transformation.7 
AP-1 activity is modulated by interactions 
with other transcriptional regulators and 
is further controlled by upstream kinases 
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that link AP-1 to various signal transduc-
tion pathways.8
AP-1 is constitutively activated in 
glial tumors,9 and directly associates 
with resistance to chemotherapy,10 and 
decreased response to apoptotic signals.11 
Malignant gliomas have an abundance 
of AP-1 stimulating signals, including 
epidermal growth factor receptor,12 and 
platelet-derived growth factor receptor,13 
and contain mutations in the p53 gene,14 
which contribute to phosphoinositide-
3-kinase (PI3K)/Akt and Ras/mitogen-
activated protein kinase activation. 
PTEN (phosphatase and tensin homo-
logue deleted on chromosome ten), a 
tumor suppressor gene commonly inac-
tivated in glioblastoma, downregulates 
AP-1, while aberrant PTEN expression 
contributes to AP-1 constitutive activa-
tion.15 Interestingly, curcumin, a natu-
rally occurring polyphenol derived from 
the root of the rhizome, Curcuma longa, 
inhibits AP-1 activation and sensitizes 
glioma cells to several clinically utilized 
chemotherapeutic agents (cisplatin, eto-
poside, camptothecin and doxorubicin) 
and radiation.16
The members of Fos protein family are 
subdivided in two main groups accord-
ing to their ability to transform rodent 
fibroblasts: transforming (c-Fos, FosB) 
and non-transforming (Fra-l and Fra-2).17 
Fra-1 (also named FOSL1), albeit unable 
to transform, is involved in the malig-
nant progression of multiple tumor types, 
including non-small cell lung carcinoma18 
and colorectal carcinoma.19 Silencing or 
knockdown of Fra-1 expression reverses 
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anti-vascular endothelial growth factor 
(VEGF) antibody has obtained acceler-
ated FDA approval for the treatment of 
recurrent glioblastoma (GBM).30 In this 
context, VEGF-D, the most recently 
described member of the VEGF family, 
has an important role to play.31 Previously, 
Debinski et al. have shown that VEGF-D 
is ubiquitously expressed in GBM under 
the tight regulation of Fra-1, which in turn 
activates VEGF receptors 2 and 3, which 
are very important for tumor angiogene-
sis.32 This was the initial report that Fra-1 
is a potential novel target for malignant 
gliomas.
Jun B is an essential gene for the normal 
embryonic development. In trophoblasts, 
the lack of JunB causes a deregulation of 
proliferin, matrix metalloproteinase-9 
(MMP-9) and urokinase plasminogen 
activator (uPA) gene expression, result-
ing in a defective neovascularization of 
the decidua and subsequent death of 
embryos.  Jun B involvement in cancer, 
however, is more complicated as it seems 
that it can both promote and hinder car-
cinogenesis.  JunB is amplified or overex-
pressed in cervical cancer cell lines34 and in 
tumor samples from patients with primary 
cutaneous T-cell lymphomas.35 However, 
Jun B can also suppress tumorigenesis,24,36 
and can maintain replicative senescence 
as a balance against excessive prolifera-
tion and carcinogenesis.37 The preferential 
association of Fra-1 and Jun B was shown 
to be related with malignant transforma-
tion of JB6 epithelial cells, with gain of 
JunB and Fra-1 binding complexes in all 
transformed cells, which might contribute 
to a more proliferative phenotype.38 The 
heterodimer Fra-1-JunB is able to regulate 
the expression of multiple genes includ-
ing the interleukin 2 (IL-2),39 and cyclin 
A,40 which in turn promote neoplastic cell 
growth and proliferation.
In the last issue of Cancer Biology & 
Therapy, Debinski and Gibo present their 
research work showing that the Fra-1-JunB 
partnership is maintained in glioma, and 
that this heterodimer binds to the AP-1 
site in the JunB promoter. Their interest 
on the Fra-1-JunB interaction stems from 
their previously published work, where 
they document that JunB is 7-fold overex-
pressed in response to ectopic Fra-1 expres-
sion in H4 malignant glioma cells.25 Such 
tumorigenicity in non-tumorigenic glioma 
cell lines.25
Malignant gliomas have long been 
known to be one of the most densely 
vascularized tumors.26 Malignant glio-
mas express high levels of VEGF, a key 
regulator of angiogenesis. Levels of VEGF 
expression correlate with both tumor 
grade and microvessel density.27-29 These 
findings suggest that therapeutic strategies 
targeting angiogenesis may provide an 
effective approach to suppress malignant 
glioma growth. Avastin (bevacizumab, 
Genentech Inc., South San Francisco, 
CA), a humanized, monoclonal, 
the malignant phenotype.20 In murine 
models, Fra-1 deletion results in severe 
growth retardation and embryonic lethal-
ity, because this transcription factor is 
critical for extra-embryonic tissue develop-
ment, namely the normal vascularization 
of the placenta.21 However, if Fra-1 dele-
tion is restricted only to the embryo, these 
mice subsequently display reduced bone 
mass formation and osteopenia.22 Fra-1 
overexpression results in osteosclerosis23 
and can lead to lung tumors.24 In glioma 
cells, Fra-1 modulates the malignant 
phenotype by altering the cell shape and 
anchorage, and its overexpression confers 
Figure 1. Fra-1 is a key regulator of multiple oncogenic pathways in malignant gliomas. Fra-1 
activation is caused by multiple pathways involved in malignant glioma progression, such as Map 
kinases (MAPK), growth factors (ERK) and the PI3K/AKT cascade. In addition, Fra-1 binds to its gene 
promoter and auto activates its transcription. In turn, Fra-1 stimulates JunB production and pairs 
with JunB. The Fra-1-JunB complex formation is associated with cell morphology changes which 
promote invasion. Fra-1 also stimulates neoangiogenesis through the VEGF-D expression.
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potential targets for the AP-1 complexes in 
both embryogenesis and in cancer—and 
the targets differ between different malig-
nancies. However, the Fra-1-JunB down-
stream targets are still elusive in gliomas.
The holy grail of glioma therapy is 
to find a potent, targeted treatment. 
Inhibition of multiple molecular pathways 
seemed promising in in vitro and in animal 
models. However, many of them failed to 
improve patients survival.41 As curcumin-
an AP-1 inhibitor seems to hold initial 
promise, it would be interesting to be able 
to develop specific compounds targeted to 
Fra-1 and other important AP-1 proteins. 
This avenue of research might permit fur-
ther refinements of our approaches to an 
almost universally deadly disease.
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